Rowlandmiller & Partners’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-479
| Closed | -$103K | – | 178 |
|
|
2024
Q1 | $103K | Sell |
479
-65
| -12% | -$15.2K | 0.02% | 180 |
|
|
2023
Q4 | $141K | Hold |
544
| – | – | 0.03% | 155 |
|
|
2023
Q3 | $140K | Hold |
544
| – | – | 0.03% | 150 |
|
|
2023
Q2 | $155K | Sell |
544
-92
| -14% | -$27.4K | 0.04% | 149 |
|
|
2023
Q1 | $177K | Sell |
636
-260
| -29% | -$71.9K | 0.04% | 142 |
|
|
2022
Q4 | $244K | Hold |
896
| – | – | 0.06% | 135 |
|
|
2022
Q3 | $239K | Hold |
896
| – | – | 0.06% | 132 |
|
|
2022
Q2 | $183K | Hold |
896
| – | – | 0.05% | 142 |
|
|
2022
Q1 | $189K | Hold |
896
| – | – | 0.04% | 141 |
|
|
2021
Q4 | $215K | Buy |
896
+230
| +35% | +$59.1K | 0.05% | 139 |
|
|
2021
Q3 | $178K | Sell |
666
-230
| -26% | -$75.4K | 0.06% | 124 |
|
|
2021
Q2 | $310K | Buy |
896
+110
| +14% | +$33.3K | 0.08% | 119 |
|
|
2021
Q1 | $220K | Hold |
786
| – | – | 0.06% | 134 |
|
|
2020
Q4 | $192K | Buy |
786
+120
| +18% | +$31K | 0.05% | 134 |
|
|
2020
Q3 | $211K | Hold |
666
| – | – | 0.08% | 107 |
|
|
2020
Q2 | $178K | Hold |
666
| – | – | 0.06% | 124 |
|
|
2020
Q1 | $211K | Buy |
666
+5
| +0.8% | +$1.52K | 0.08% | 107 |
|
|
2019
Q4 | $196K | Hold |
661
| – | – | 0.06% | 124 |
|
|
2019
Q3 | $154K | Hold |
661
| – | – | 0.05% | 123 |
|
|
2019
Q2 | $155K | Buy |
661
+125
| +23% | +$28.9K | 0.05% | 124 |
|
|
2019
Q1 | $127K | Hold |
536
| – | – | 0.05% | 128 |
|
|
2018
Q4 | $161K | Buy |
536
+30
| +6% | +$9.57K | 0.07% | 111 |
|
|
2018
Q3 | $179K | Hold |
506
| – | – | 0.06% | 115 |
|
|
2018
Q2 | $147K | Hold |
506
| – | – | 0.06% | 119 |
|
|
2018
Q1 | $139K | Hold |
506
| – | – | 0.06% | 119 |
|
|
2017
Q4 | $162K | Sell |
506
-1,544
| -75% | -$495K | 0.06% | 111 |
|
|
2017
Q3 | $375K | Buy |
2,050
+1,544
| +305% | +$457K | 0.16% | 78 |
|
|
2017
Q2 | $137K | Hold |
506
| – | – | 0.06% | 115 |
|
|
2017
Q1 | $138K | Hold |
506
| – | – | 0.06% | 114 |
|
|
2016
Q4 | $144K | Hold |
506
| – | – | 0.07% | 108 |
|
|
2016
Q3 | $158K | Hold |
506
| – | – | 0.07% | 105 |
|
|
2016
Q2 | $123K | Buy |
+506
| New | +$133K | 0.06% | 113 |
|
|
2016
Q1 | – | Sell |
-376
| Closed | -$111K | – | 124 |
|
|
2015
Q4 | $111K | Hold |
376
| – | – | 0.06% | 121 |
|
|
2015
Q3 | $110K | Hold |
376
| – | – | 0.06% | 118 |
|
|
2015
Q2 | $152K | Hold |
376
| – | – | 0.08% | 110 |
|
|
2015
Q1 | $155K | Hold |
376
| – | – | 0.08% | 105 |
|
|
2014
Q4 | $128K | Buy |
+376
| New | +$122K | 0.06% | 111 |
|
Other funds holding BIIB
Rowlandmiller & Partners's BIIB Position: Q2 2024 in Review
Rowlandmiller & Partners sold out of Biogen (BIIB) in Q2 2024, closing a stake of 479 shares — an estimated $103K sold.
Rowlandmiller & Partners first reported a position in BIIB in Q4 2014 and held it in 37 quarters. The position peaked at $375K in Q3 2017. 944 funds tracked by Wall St. Rank hold BIIB as of Q2 2024.
- Rowlandmiller & Partners reported no remaining Biogen position as of Q2 2024 after selling out during the quarter.
- Rowlandmiller & Partners sold 479 Biogen shares in Q2 2024, an estimated $103K.
- Rowlandmiller & Partners first reported a position in Biogen in Q4 2014 and held it in 37 quarters.
- Rowlandmiller & Partners's Biogen position peaked at $375K in Q3 2017.
- 944 funds tracked by Wall St. Rank held Biogen as of Q2 2024.
Based on Rowlandmiller & Partners's 13F filing for Q2 2024, filed 29 Jul 2024.